

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Amendment No.: *

Name of Issuer: Myriad Genetics, Inc.

Title of Class of Securities: Common Stock, par value \$.01 per share

CUSIP Number: 62855J104

(Name, Address and Telephone Number of Person
Authorized To Receive Notices and Communications)

UBS Asset Management (New York) Inc.
1345 Avenue of the Americas New York, New York 10105
Attention: Roslyn M. Allison
Telephone No. (212) 649-7103

(Date of Event which Requires Filing of this Statement)

August 27, 1997

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [].

Check the following line if a fee is being paid with this statement. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of class. See Rule 13d-7).

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 62855J104

1. Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person

UBS Asset Management (New York) Inc.
13-27-25861

2. Check the Appropriate Box if a Member of a Group

- a.
b.

3. SEC Use Only

4. Source of Funds

00

5. Check if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

New York

Number of Shares Beneficially Owned by Each Reporting Person
With:

7. Sole Voting Power:

None

8. Shared Voting Power:

None

9. Sole Dispositive Power:

480,000

10. Shared Dispositive Power:

None

11. Aggregate Amount Beneficially Owned by Each Reporting Person

480,000

12. Check Box if the Aggregate Amount in Row (11) Excludes
Certain Shares

13. Percent of Class Represented by Amount in Row (11)

3
5.2%

14. Type of Reporting Person

IA

CUSIP No.62855J104

1. Name of Reporting Person

S.S. or I.R.S. Identification No. of Above Person

UBS (Lux) Equity Invest - Biotech, a subfund of UBS (Lux) Equity Invest
c/o INTRAG International Equity Invest (Company for Fund Management) S.A.
3-5, Place Winston Churchill, B.P. 134, 2011 Luxembourg
Attention: Dr. Heinz Hammerli

2. Check the Appropriate Box if a Member of a Group

- a.
- b.

3. SEC Use Only

4. Source of Funds

00

5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

Luxembourg

Number of Shares Beneficially Owned by Each Reporting Person
With:

7. Sole Voting Power:

480,000

8. Shared Voting Power:

None

9. Sole Dispositive Power:

None

10. Shared Dispositive Power:

None

11. Aggregate Amount Beneficially Owned by Each Reporting Person

480,000

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

5

13. Percent of Class Represented by Amount in Row (11)

5.2%

14. Type of Reporting Person

00

Item 1. Security and Issuer

The title of the class of equity securities to which this statement relates is: Common Stock, \$0.01 par value of Myriad Genetics, Inc. (the "Issuer").

The name and address of the principal executive and business office of the Issuer is:

320 Wakara Way
Salt Lake City, Utah 84108

Item 2. Identity and Background

(a) UBS Asset Management (New York) Inc. ("UBSAM"). UBSAM is a registered investment adviser which serves pursuant to an agreement as portfolio manager for UBS (Lux) Equity Invest - Biotech. A list of the directors and executive officers of UBSAM appears in Appendix A. UBSAM is a wholly-owned subsidiary of UBS Inc. UBS Inc. is a wholly-owned subsidiary of Union Bank of Switzerland, a company organized under the laws of Switzerland. Union Bank of Switzerland is principally engaged in general banking business. A list of the directors and executive officers of UBS Inc. and Union Bank of Switzerland appears in Appendix A.

UBS (Lux) Equity Invest - Biotech is a subfund of the investment fund UBS (Lux) Equity Invest. UBS (Lux) Equity Invest has been established by INTRAG International Equity Invest (Company for Fund Management) S.A. in collaboration with Union Bank of Switzerland, Zurich and Union de Banques Suisses (Luxembourg) S.A. as an open-end investment fund under Luxembourg law. INTRAG International Equity Invest (Company for Fund Management) S.A. was established as a subsidiary of INTRAG, Zurich, as a public limited company in Luxembourg for the purpose of managing UBS (Lux) Equity Invest. A list of the Directors and Executive Officers of INTRAG International Equity Invest (Company for Fund Management) S.A. appears in Appendix B.

(b) The address of UBSAM is 1345 Avenue of the Americas, New York, New York 10105. The address of each of the directors and executive officers of UBSAM (except for directors or executive officers who are also directors or officers of UBS Inc. or Union Bank of Switzerland) is 1345 Avenue of the Americas, New York, New York 10105. The address of each of the directors and executive officers of UBS Inc. (except for directors or executive officers who are also directors or executive officers of Union Bank of Switzerland) is 299 Park Avenue, New York, New York 10171. The address of each of the directors and executive officers of Union Bank of Switzerland is c/o Union Bank of Switzerland, Bahnhofstrasse 45, 8021 Zurich, Switzerland.

The address of UBS (Lux) Equity Invest - Biotech is c/o INTRAG International Equity Invest (Company for Fund Management) S.A., 3-5, Place Winston Churchill, B.P. 134, 2011 Luxembourg. The address of each of the directors and executive officers of INTRAG International Equity Invest (Company for Fund Management) S.A. appears in Appendix B.

(c) The present principal occupation or employment of each of the directors and executive officers of each of UBSAM, UBS Inc and Union Bank of Switzerland are set forth in Appendix A.

The present principal occupation or employment of each of the directors and executive officers of each of INTRAG International Equity Invest (Company for Fund Management) S.A. are set forth in Appendix B.

(d) During the past five years, neither UBSAM, UBS Inc. nor Union Bank of Switzerland nor, to the knowledge of UBSAM, any of the directors or executive officers of UBSAM, UBS Inc. or Union Bank of Switzerland has been convicted in any criminal proceeding, excluding traffic violations or similar misdemeanors.

During the past five years, neither INTRAG International Equity Invest (Company for Fund Management) S.A. nor, to the knowledge of INTRAG International Equity Invest (Company for Fund Management) S.A., any of the directors or executive officers of INTRAG International Equity Invest (Company for Fund Management) S.A. has been convicted in any criminal proceeding, excluding traffic violations or similar misdemeanors.

(e) During the past five years, neither UBSAM, UBS Inc. nor Union Bank of Switzerland nor, to the knowledge of UBSAM, any of the directors or executive officers of UBSAM, UBS Inc. or Union Bank of Switzerland has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which it or such person is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

During the past five years, neither INTRAG International Equity Invest (Company for Fund Management) S.A. nor, to the knowledge of INTRAG International Equity Invest (Company for Fund Management) S.A., any of the directors or executive officers of INTRAG International Equity Invest (Company for Fund Management) S.A. has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which it or such person is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) UBSAM is organized under the laws of New York. UBS Inc. is organized under the laws of New York and Union Bank of Switzerland is organized under the laws of Switzerland. Each director and executive officer of UBSAM (except for Mr. Arthur Decurtins and Mr. James Patrick McCaughan) is a citizen of the United States. To the knowledge of UBSAM, none of the directors or executive officers of Union Bank of Switzerland are citizens of the United States.

INTRAG International Equity Invest (Company for Fund Management) S.A. is organized under the laws of Luxembourg. None of the directors or executive officers of INTRAG International Equity Invest (Company for Fund Management) S.A. are citizens of the United States.

Item 3. Source and Amount of Funds or Other Consideration.

As described in Item 2(a) above, UBSAM exercises investment discretion with respect to the of UBS (LUX) Equity Invest - Biotech. In that capacity, UBSAM purchased the Shares, which are the subject of this Schedule 13D, on behalf of UBS (LUX) Equity Invest - Biotech. The funds for the purchase of the Shares came from participants' investments in UBS (LUX) Equity Invest - Biotech. No funds were borrowed to finance the purchase. UBS (LUX) Equity Invest - Biotech maintains sole voting rights with regard to the Shares.

Item 4. Purpose of Transactions.

(a) The Shares held by the UBSAM were acquired for, and are being held for, investment purposes. The acquisitions of the Shares described herein were made in the ordinary course of UBSAM's investment activities. UBSAM, on behalf of UBS (LUX) Equity Invest - Biotech, reserves the right to purchase or sell Shares in privately negotiated transactions or in any other lawful manner in the future.

(b) Planned/proposed extraordinary corporate transaction involving issuer or its subsidiaries. Not applicable.

(c) Planned/proposed material sale/transfer of assets of issuer or its subsidiaries. Not applicable.

(d) Planned/proposed change to the Board or Management of the Issuer. Not applicable.

(e) Planned/proposed material change to the capitalization/dividend policy of the issuer. Not applicable.

(f) Planned/proposed material change to the issuer's business or corporate structure. Not applicable.

(g) Planned/proposed changes in the issuer's charter, bylaws, or instruments that may impede the acquisition of control of the issuer by any person. Not applicable.

(h) Plans/proposals to cause a class of security of the issuer to be delisted. Not applicable.

(i) Plans/proposals to cause a class of equity to become eligible for termination of registration pursuant to Section 12(g)(4). Not applicable.

(j) Plans/proposals similar to any of the above. Not applicable.

Item 5. Interest in Securities of Issuer.

(a) Based on information obtained from the Issuer, 9,199,546 shares are believed to be outstanding. As of August 28, 1997, UBSAM and UBS (LUX) Equity Invest - Biotech were deemed to be the beneficial owners of 480,000 Shares which represented 5.2% of the Issuer's outstanding shares. UBS Inc. and Union Bank of Switzerland through their direct and indirect ownership of UBSAM, may be deemed to be indirect beneficial owners of the Shares.

(b) UBSAM has the sole power to dispose of all the shares. INTRAG International Equity Invest (Company for Subfund Management) S.A. has the sole power to vote all the shares.

(c) All transactions in the Shares effected by UBSAM during the sixty days prior to August 28, 1997 were effected in open-market transactions and are set forth in Exhibit C hereto.

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Shares.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Except as described herein, there are no contracts, arrangements, understandings or relationships between the persons named in Item 2 hereof or between such persons and any other person with respect to any securities of the Issuer.

Item 7. Material to be Filed as Exhibits.

Exhibit A. List of Directors and Executive Officers of UBSAM, UBS Inc. and Union Bank of Switzerland and their respective present principal occupation or employment.

Exhibit B. List of Directors and Executive Officers of INTRAG International Equity Invest (Company for Fund Management) S.A. and their respective present principal occupation or employment and addresses

Exhibit C. Schedule of Transactions in the Shares made by UBSAM.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

September 16, 1997

- -----
Date

UBS Asset Management (New York) Inc.

/s/ Roslyn M. Allison

- -----
Title: Vice President, Compliance Department

INTRAG International Equity Invest (Company for Fund Management) S.A.

/s/ Heinz Hammerli

- -----
Title: Chairman of the Board

EXHIBIT INDEX

Exhibit A. List of Directors and Executive Officers of UBSAM, UBS Inc. and Union Bank of Switzerland and their respective present principal occupation or employment.

Exhibit B. List of Directors and Executive Officers of INTRAG International Equity Invest (Company for Fund Management) S.A. and their respective present principal occupation or employment and addresses

Exhibit C. Schedule of Transactions in the Shares made by UBSAM.

EXHIBIT A

UBSAM BOARD OF DIRECTORS and EXECUTIVE OFFICERS

Arthur Decurtins	Chairman
James Patrick McCaughan	Managing Director and President
Henry William Haunss, Jr.	Managing Director
Robert Charles Dinerstein	Director and Corporate Secretary
Victor Henry Romley	Managing Director
Richard Ciro Capone	Director
George Jamgochian	Managing Director
Amy Morlock McNally	Functional Vice President
Ranjani H. Nagaswami	Vice President
Wayne D. Thornbrough	Managing Director

UBS INC.
BOARD OF DIRECTORS AND EXECUTIVE OFFICERS

Cabiallavetta, Mathis	Vice Chairman
Capone, Richard C.	President
Bozian, Alan G.	Senior Managing Director
Brown, Gary	Senior Managing Director
Dinerstein, Robert C.	Senior Managing Director and Secretary
Ahearn, Michael J.	Managing Director
Asjes, Dick	Managing Director
Barbian, Paul	Managing Director
Cantalini, James	Managing Director
Casey, Robert W.	Managing Director
Charleson, Lawrence	Managing Director
Coe, Mary B. W.	Managing Director
Criswell, Christopher W.	Managing Director
Henderson, Dennis B.	Managing Director
Hoban, Patrick N.	Managing Director
Imholz, Alfred	Managing Director
James, W. Scott	Managing Director
Lynch, Gary Charles	Managing Director
Sperry, L. Thomas	Managing Director
Ullrich, G. Christian	Managing Director
Whitworth, David T.	Managing Director
Yearley, Peter B.	Managing Director
Chaix, Laurent	Vice President
Delloso, Stephan	Vice President
Etter, Marcel	Vice President
Feld, Lisa B.	Vice President
Mendelsohn, Bruce	Vice President
Michaelis, A. Jane	Vice President
Saliling, Julie	Vice President
Lange, Kevin A.	Vice President
Wojcechowskyj, Stephan	Vice President
O'Rourke, Donna	Assistant Vice President
Satz, Eric	Assistant Vice President
Travers, Jayne	Assistant Vice President
Power, Jennifer	Credit Admin Officer
Chen, Carol	Assistant Treasurer
Blanck, Barbara	Assistant Secretary

UNION BANK OF SWITZERLAND
BOARD OF DIRECTORS

Robert Studer*	Schonenberg, Chairman
Hans Heckmann*	Schlieren, Vice Chairman
Markus Kundig*	Zug, Vice Chairman, Publisher
Marc C. Cappis	Herisau, Managing Director of Huber + Suhner Ltd., Herisau AR/Pfaffikon ZH
Fritz Fahrni	Islikon, President of the Corporate Executive Management of Sulzer Ltd., Winterthur
Kurt E. Feller	Wollerau, Managing Director and Chief Executive Officer of Rieter Holding Ltd., Winterthur
Charles R. Firmenich	Genthod, Vice Chairman of the Board of Firmenich (International) SA, Geneva
Hannes Goetz*	Ruschlikon, Chairman of the Board of Swissair, Zurich Airport
Reto Mengiardi	Chur, Attorney and Notary Public
Rolf A. Meyer*	Basle, Chief Financial Officer and Member of the Executive Committee of Ciba-Geigy Ltd., Basle
Anne-Lise Monnier-Blaile	Gland, Pharmacist and Chairwoman of the Board of Ofac, Geneva
Andreas Reinhart*	Winterthur, Chairman of the Board of Volkart Brothers Holding Ltd., Winterthur
Maria Reinshagen	Zurich, Vice President of Christie's (International) SA Switzerland
Rene K. Ruepp	Pfaffhausen, Chairman of the Board and Chief Executive Officer of Forbo Holding SA, Eglisau
Alfred N. Schindler*	Hergiswil, Vice Chairman and Chief Executive Officer of Schindler Holding AG, Hergiswil
Johann-Niklaus Schneider- Ammann	Langenthal, Chairman of the Board and Managing Director of the Ammann Group, Langenthal
Manfred Zobl	Ruschlikon, Chairman of the Corporate Executive Board of Swiss Life/Rentenanstalt, Zurich

*Member of the Board of Directors Committee

UNION BANK OF SWITZERLAND
GROUP EXECUTIVE BOARD

Mathis Cabiallavetta	President of the Group Executive Board
Werner Bonadurer	Executive Vice President
Arthur Decurtins	Executive Vice President
Ulrich Grete	Executive Vice President
Felix Fischer	Executive Vice President
Stephan Haeringer	Executive Vice President
Pierre de Weck	Executive Vice President

EXHIBIT B

INTRAG INTERNATIONAL EQUITY INVEST (COMPANY FOR FUND MANAGEMENT)
S.A. BOARD OF DIRECTORS and EXECUTIVE OFFICERS

Heinz Hammerli	Chairman (General Manager, INTRAG (Zurich) INTRAG, Bahnhofstrasse 45, 8021 Zurich, Switzerland
Manuel Hauser	Director (Executive Director, UBS - Intrag (Services) S.A. Luxembourg) INTRAG International Equity Invest (Company for Fund Management) S.A., 3-5, Place Winston Churchill, B.P. 134, 2011 Luxembourg
Dr. Antoni M. Stankiewicz	Director (First Vice President, Union Bank of Switzerland, Zurich) Union Bank of Switzerland, Bahnhofstrasse 45, 8021 Zurich, Switzerland

EXHIBIT C

SCHEDULE OF TRANSACTIONS

Date - - - - -	Shares Acquired or (Sold) - - - - -	Price Per Share (Excluding Commission) - - - - -
7/14/97	28,500	\$25.63
7/30/97	1,100	\$24.88
7/30/97	30,000	\$25.25
7/31/97	20,000	\$25.88
8/1/97	8,900	\$25.63
8/4/97	10,000	\$25.75
8/6/97	(3,828)	\$25.45
8/6/97	(1,094)	\$25.45
8/6/97	(3,281)	\$25.45
8/6/97	(1,641)	\$25.45
8/6/97	(547)	\$25.45
8/6/97	(2,188)	\$25.45
8/6/97	(547)	\$25.45
8/6/97	(1,094)	\$25.45
8/6/97	(2,188)	\$25.45
8/6/97	(547)	\$25.45
8/6/97	(547)	\$25.45
8/6/97	(547)	\$25.45
8/6/97	(820)	\$25.45
8/6/97	(820)	\$25.45
8/6/97	(875)	\$25.45
8/6/97	(1,641)	\$25.45
8/6/97	(273)	\$25.45

8/6/97	(109)	\$25.45
8/6/97	(820)	\$25.45
8/6/97	(820)	\$25.45
8/6/97	(3,177)	\$25.45
8/6/97	(120)	\$25.45
8/6/97	(3,281)	\$25.45
8/6/97	(2,188)	\$25.45
8/6/97	(973)	\$25.45
8/6/97	(1,094)	\$25.45
8/7/97	20,000	\$24.22
8/7/97	10,000	\$24.04
8/7/97	5,000	\$24.04
8/7/97	20,000	\$24.48
8/12/97	7,500	\$24.75
8/12/97	10,000	\$24.75
8/13/97	5,000	\$24.19
8/13/97	10,000	\$24.38
8/13/97	4,400	\$24.54
8/14/97	10,000	\$24.75
8/15/97	10,000	\$25.13
8/15/97	4,100	\$24.98
8/15/97	10,000	\$25.00
8/18/97	4,000	\$24.81
8/18/97	5,000	\$24.75
8/18/97	10,000	\$24.75
8/19/97	5,000	\$24.38
8/20/97	15,000	\$24.79

8/27/97	10,000	\$23.88
8/28/97	20,000	\$23.63